Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INHALAVID trial of early inhaled budesonide + formoterol versus standard of care in vulnerable patients with COVID-19
2020-005280-31Phase 4Active
- Sponsor
- Eurecat
- Start
- Feb 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of budesonide and formoterol in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Eurecat. Primary endpoint: Change in Dublin-Boston score from day 0 to day 4. Started Feb 2021; status: active.
02
Drugs
budesonideformoterol
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-005280-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005280-31.